Gulbarga, India
Gulbarga, India

Time filter

Source Type

News Article | May 22, 2017
Site: www.businesswire.com

MAYSVILLE, Ky.--(BUSINESS WIRE)--Meadowview Regional Medical Center today announced that it has been named a Duke LifePoint Quality Affiliate. This designation recognizes hospitals within the LifePoint Health system that have enrolled in the LifePoint National Quality Program and succeeded in transforming their culture of safety and achieving high standards of quality care, performance improvement and patient engagement. “Meadowview Regional Medical Center has a long legacy of providing high quality care, and earning this esteemed designation is just one more way the hospital is making the Maysville community healthier,” said Joe Koch, chief executive officer of Meadowview Regional Medical Center. “I am so proud to be part of the Meadowview team and look forward to continuing the hospital’s great work to improve patient care, safety and satisfaction long into the future.” Meadowview Regional Medical Center is a 100-bed, acute-care facility serving people in the Maysville, Ky., community and surrounding areas. To achieve Duke LifePoint Quality Affiliate designation, the Meadowview team worked to implement a number of best practices and launch new initiatives to engage patients and families, enhance patient safety and improve quality care. For example, the hospital initiated leadership safety briefings each morning to ensure that leaders have a regular proactive planning session to address patient concerns. The hospital also implemented bedside shift reporting to help ensure clear communication, reduce the risk of errors and maintain consistency of care during shift changes. Bedside shift reporting is an effective method for transferring information from one provider to another, while also involving the patient in discussions about their health, progress and treatment plan. Additionally, Meadowview established a Community Collaborative in an effort to work closely with other healthcare providers and organizations in the community to help reduce avoidable patient readmissions. “At LifePoint, quality is truly at the core of our culture and operations, and Meadowview has gone above and beyond to satisfy the rigorous requirements necessary to be named a Duke LifePoint Quality Affiliate,” said David Dill, president and chief operating officer of LifePoint Health. “We are delighted to recognize this high-performing facility and commend the many improvements it has made to take even better care of patients and their families.” The LifePoint National Quality Program was created through a collaboration between LifePoint Health and Duke University Health System. When hospitals enroll in the program, they begin working with Duke and LifePoint quality coaches to evaluate and strengthen their quality programs and processes. Following an initial evaluation, the hospital creates a plan and begins to deploy changes that will help it achieve quality improvement benchmarks and establish long-term solutions to sustain its results. In addition to evaluating common quality care and patient safety metrics, the LifePoint National Quality Program focuses on foundational elements required to sustain quality care, including committed leadership, systems to ensure continuous performance and process improvement, and a culture dedicated to safety. Duke LifePoint Quality Affiliate designation denotes those hospitals that achieve a broad range of criteria in each of these areas and demonstrate a capacity to continuously measure and improve quality and patient safety. MRMC is a 100-bed acute care facility located along the Ohio River in Maysville, Kentucky. The service area consists of five counties in Kentucky and two counties in Ohio. Delivering quality healthcare close to home is the single most important contribution we make in achieving our mission of Making Communities Healthier®. Our medical staff consists of well-trained physicians covering a number of specialties, including Allergy, Anesthesia, Cardiology, Emergency Medicine, Endocrinology, Family Practice, Gastroenterology, General Surgery, Hematology/Oncology, Hospitalist, Internal Medicine, Nephrology, Neurology, Obstetrics/Gynecology, Ophthalmology, Orthopedics, Otolaryngology, Pathology, Pediatrics, Podiatry, Radiation Therapy, Radiology, Sleep Medicine and Urology. For more information, visit www.MeadowviewRegional.com. LifePoint Health (NASDAQ: LPNT) is a leading healthcare company dedicated to Making Communities Healthier®. Through its subsidiaries, it provides quality inpatient, outpatient and post-acute services close to home. LifePoint owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in 22 states. It is the sole community healthcare provider in the majority of the non-urban communities it serves. More information about the company can be found at www.LifePointHealth.net.


News Article | May 17, 2017
Site: www.prweb.com

Intrinsic Imaging, a full-service medical imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials, announces today the award of another multiple-reader multiple-case (MRMC) study to assess the clinical performance of computer aided detection (CAD) software. Throughout this trial, Intrinsic Imaging will provide comprehensive core lab services and manage all aspects of the clinical trial. These services include providing medical guidance and all case reviewers who will perform over 14,400 reviews without CAD and with CAD to evaluate the software’s clinical performance. Intrinsic Imaging’s MRMC CAD Team was selected for this trial due to its operational success in successfully completing many MRMC CAD studies that have resulted in multiple FDA clearances of computer aided detection software. “Intrinsic Imaging is the industry leader in conducting large multi-reader multi-case CAD trials,” said Todd Joron, President and COO at Intrinsic Imaging. “Whether it be conventional CAD, artificial intelligence (AI) or other machine learning software, Intrinsic Imaging’s success in managing MRMC studies brings unmatched value to clients looking to assess the clinical performance of their computer aided detection software.” This trial will be conducted within Intrinsic Imaging’s quality framework. With its portfolio of five ISO certifications, Intrinsic Imaging has the most comprehensive and sophisticated quality management system in the industry. Intrinsic Imaging is a full-service medical imaging core lab providing comprehensive services in support of Phase I-IV Clinical Trials and Class I, II, III Medical Device Trials. Our team consists of more than 70 full-time, board-certified, fellowship trained radiologists and 100 consulting radiologists and key opinion leaders. Our Team has sub-specialization in all therapeutic areas including Cardiovascular, Metabolic & Pulmonary, Gastrointestinal & Genitourinary, Medical Device, Musculoskeletal, Neuroradiology and Oncology. With our medical expertise, operational excellence and scalable technology, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world.


News Article | May 23, 2017
Site: www.businesswire.com

AUCKLAND, New Zealand--(BUSINESS WIRE)--Regenerative medicine start-up Upside Biotechnologies has signed a CRADA (Cooperative Research and Development Agreement) with the US Army Medical Research and Materiel Command (USAMRMC) based in Fort Detrick, Maryland. The CRADA initiates a collaboration on both the scientific and regulatory aspects of Upside’s engineered skin product development. New Zealand-based Upside is developing an advanced, world-class skin replacement treatment for patients suffering major burns. Upside CEO Dr Robert Feldman says the USAMRMC has an unparalleled depth of experience in the development and treatment of major burns. “This US Army input will be hugely valuable to Upside and will fully assist us in successfully progressing our product to the benefit of all burn sufferers, including US warriors,” Dr Feldman says. “The USAMRMC is pleased to provide guidance to Upside Biotechnologies as it navigates the US FDA approval process for a novel skin replacement product,” says Susan Taylor, product manager for the Tissue Injury and Regenerative Medicine Project Management Office at the US Army Medical Materiel Development Activity, USAMRMC. “This product may provide a critical solution in the treatment of service members who have sustained severe burns. Our goal is to help Upside move this product as quickly and as safely as possible through the regulatory process, so it is available to our wounded service members.” This regenerative medicine company’s technology enables a small sample of unburnt patient skin to be grown in the laboratory into large areas of full thickness skin. This lab-grown skin can be used as skin grafts in patients with major burns who do not have enough uninjured skin to provide conventional skin grafts. Upside skin is produced faster than any competitive product in development. It is supplied in larger sheets with handling characteristics preferred by burns surgeons. The company recently announced it had raised $2.3m in its Series A funding round. The US Army Medical Research and Materiel Command is the Army's medical materiel developer, with responsibility for medical research, development, and acquisition and medical logistics management. The USAMRMC's expertise in these critical areas helps establish and maintain the capabilities the Army needs to fight and win on the battlefield. The Command is headquartered at Fort Detrick.


Parameshwarappa K.D.,BIRMS | Chandrakanth C.,BIRMS | Sunil B.,MRMC
Journal of Clinical and Diagnostic Research | Year: 2012

Aims and Objectives: The intestinal parasitic infections which are prevalent in the developing countries may even be more important than the bacterial infections. In India, malnutrition, unhygienic conditions, the improper disposal of sewage, the non-availability of potable water supplies in the rural and the urban areas, the indifferent attitude of the population towards personal hygiene, their low socio-economic status and the low literacy rates are responsible for the high rates of intestinal parasitic infections. In view of the above facts, the present study was undertaken to assess the prevalence of the intestinal parasitic infections in the urban and the rural populations which came under a tertiary care teaching hospital. Material and Methods: A total of 1000 stool samples were collected from the rural and the urban populations and each stool sample was examined by: 1. Gross examination 2. Direct microscopic examination by using saline and iodine preparations and by 3. Concentration techniques like simple slat flotation, Zinc sulphate centrifugal floatation, formol-ether concentration and modified formol-ether concentration. Results: The prevalence of the intestinal parasitic infections was higher in the rural population. A male predominance was noted (33.29%) in both the populations. Children who were between 10-20 years of age had the highest prevalence of the parasitic infestations. The common parasite which was isolated from both the populations was Entamoeba histolytica, with a prevalence rate of 65.57%, followed by Ascaris lumbricoides. Conclusion: The modified formol-ether sedimentation procedure showed a high sensitivity for the parasitic detection. The supplementation of the routine method with floatation and the sedimentation technique will improve the diagnostic accuracy when this is compared to the routine method alone.


KILGORE, Texas, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Martin Midstream Partners L.P. (Nasdaq:MMLP) (the "Partnership") announced today its financial results for the year ended December 31, 2016. Ruben Martin, President and Chief Executive Officer of Martin Midstream GP LLC, the general partner of the Partnership said, "I am pleased to announce the acquisition of the Hondo, Texas asphalt terminal facility for $27.4 million from Martin Resource Management Corporation (“MRMC”).  In addition, the Partnership expects to spend $8.6 million to complete construction.  The terminal will be supported by long-term contractual agreements with MRMC whereby the Partnership expects to receive cash flow of approximately $5.0 million annually.   The acquisition of a newly constructed asset at an accretive multiple of cash flow restores growth at the Partnership. “During the fourth quarter, the Partnership continued to execute on its stated goals to create balance sheet improvement and strengthen our distribution coverage ratio.  The Partnership made a strategic decision in the second half of the year to divest of the Corpus Christi terminal assets as throughput at the facility continued to decline commensurate with Eagle Ford crude oil production.  In addition to successfully closing the divestiture, we also saw the positive impact of working capital reductions during the quarter in our natural gas liquids businesses.  The net result of those two actions reduced leverage by approximately 0.3 turns on our debt to EBITDA leverage ratio at year end as well as providing additional liquidity. “For the quarter ended December 31, 2016, our distribution coverage ratio was 1.98 times based on our current quarterly distribution of $0.50.  We generated the highest level of adjusted EBITDA in the Partnership’s history based on strong contributions from our Natural Gas Services segment. We performed above expectations in our Cardinal Gas Storage line of business and met forecast in our refinery grade butane division. “Looking at our segments, the Natural Gas Services segment generated better than expected cash flow from our Cardinal Gas Storage assets.  Cardinal continues to perform exceedingly well, particularly within its interruptible services line of business.  I am especially pleased with Cardinal’s performance given the re-contracting requirements at our Arcadia, Louisiana location in mid-year 2016.   I believe the market continues to value the strategic location of our storage assets amidst the changing geographical flow of natural gas.  Additionally, our butane optimization business performed at a high level during the fourth quarter and in calendar 2016.  This performance was anticipated as the Partnership had a strong storage season during the second and third quarters of 2016.  Based on current fundamentals, we anticipate our butane business will continue to be strong during the first quarter of 2017.  The Natural Gas Services segment fell short of full year 2016 cash flow guidance by approximately $5.5 million.  However, giving effect to the previously disclosed West Texas LPG Pipeline tariff reductions and corresponding distribution to the Partnership, the segment actually outperformed our estimates by $1.4 million. “Within our Terminalling & Storage segment, our Smackover refinery exceeded cash flow forecast in 2016 primarily as a result of increased tolling and reservation fees. Positively, within this segment, we were able to significantly reduce operating expenses within our specialty terminals which offset the decline in revenues we experienced through reduced throughput.  We experienced weaker margins in our lubricants platform throughout most of 2016, partially offset by the strengths in our grease business.  For the year, the Terminalling & Storage segment was below our cash flow guidance by approximately $2.5 million. “Within our Sulfur Services segment, the Partnership significantly exceeded expectations. This is primarily attributed to strength in our fertilizer business in the second and fourth quarters. Margins were consistently strong as sulfur and raw material costs associated with our products fell throughout the year. Additionally, product demand preferences trended toward our higher margin products again in 2016.  For the year, the Sulfur Services segment exceeded our cash flow guidance by approximately $5.8 million. “Lastly, our Marine Transportation segment encountered soft market conditions during 2016.  Day rates for our assets continue to be weak even as the Partnership successfully reduced operating and general and administrative expenses during the year.  Additionally, the Partnership has reduced its fleet size by divesting of non-commercially competitive equipment.  This resulted in a non-cash asset impairment of approximately $11.7 million, negatively impacting the Partnership’s net income for 2016.  These divestitures are expected to allow the Partnership to benefit from operating expense savings of approximately $1.4 million annually.  For the year, the Marine Transportation segment was below cash flow guidance by approximately $6.1 million. “De-levering will be a top priority of the Partnership in 2017.  Based on our current annualized distribution run-rate of $2.00, the Partnership is well-positioned to continue generating strong distribution coverage while continuing to improve our balance sheet.” The Partnership had net income for the fourth quarter of 2016 of $17.9 million, or $0.49 per limited partner unit.  For the fourth quarter of 2016, net income was positively impacted by the gain on disposition of the Partnership's terminalling assets located in Corpus Christi, Texas of $37.3 million and negatively impacted by non-cash impairment charges of $27.0 million.  Of these non-cash impairment charges, $15.3 million occurred in our Terminalling and Storage segment and was related to the discontinuation of certain organic growth projects no longer deemed economically viable.  Additionally, our Marine Transportation segment experienced an $11.7 million non-cash charge related to the planned disposal of certain inland and offshore non-core transportation assets.  The Partnership had net income for the fourth quarter of 2015 of $6.8 million, or $0.08 per limited partner unit.  For the fourth quarter of 2015, net income was negatively impacted by non-cash impairment charges of $10.6 million.  These non-cash charges impacted earnings but had no impact on distributable cash flow or adjusted EBITDA.  The Partnership's adjusted EBITDA from continuing operations for the fourth quarter of 2016 was $52.3 million compared to adjusted EBITDA from continuing operations for the fourth quarter of 2015 of $51.4 million, an increase of 2%. Net income from continuing operations for the year ended December 31, 2016 was $31.7 million, or $0.65 per limited partner unit.  Net income for the year ended December 31, 2016 was positively impacted by the gain on disposition of the Partnership's terminalling assets located in Corpus Christi, Texas of $37.3 million and negatively impacted by non-cash impairment charges of $31.1 million.  Of these non-cash impairment charges, $15.3 million occurred in our Terminalling and Storage segment and was related to the discontinuation of certain organic growth projects no longer deemed economically viable.  Additionally, our Marine Transportation segment experienced an $11.7 million non-cash charge related to the planned disposal of certain inland and offshore non-core transportation assets and a $4.1 million non-cash goodwill impairment charge. Net income from continuing operations for the year ended December 31, 2015 was $37.2 million, or $0.60 per limited partner unit.  Net income for the year ended December 31, 2015 was negatively impacted by non-cash impairment charges of $10.6 million in our Terminalling and Storage segment related to the discontinuation of certain organic growth projects no longer deemed economically viable.  The Partnership's adjusted EBITDA from continuing operations for the year ended December 31, 2016 was $176.6 million compared to adjusted EBITDA from continuing operations for the year ended December 31, 2015 of $188.3 million, a decrease of 6%. The Partnership's distributable cash flow from continuing operations for both the fourth quarter of 2016 and 2015 was $35.8 million. The Partnership's distributable cash flow from continuing operations for the year ended December 31, 2016 was $113.7 million compared to distributable cash flow from continuing operations for the year ended December 31, 2015 of $133.9 million, a decrease of 15%. Revenues for the fourth quarter of 2016 were $236.9 million compared to $254.4 million for the fourth quarter of 2015.  Revenues for the year ended December 31, 2016 were $827.4 million compared to $1.0 billion for the year ended December 31, 2015.             On February 12, 2015, the Partnership exited the natural gas liquids floating storage and trans-loading businesses as a result of the sale of its six liquefied petroleum gas pressure barges, collectively referred to as the "Floating Storage Assets", for $41.3 million.  The Partnership recorded a gain on the disposition of $1.5 million. The Partnership had no net income, distributable cash flow or adjusted EBITDA from discontinued operations related to the Floating Storage Assets for the three and twelve months ended December 31, 2016. The Partnership had no net income, distributable cash flow or adjusted EBITDA from discontinued operations related to the Floating Storage Assets for the three months ended December 31, 2015.  The Partnership had net income from discontinued operations for the twelve months ended December 31, 2015 of $1.2 million, or $0.02 per limited partner unit.  Distributable cash flow and adjusted EBITDA from discontinued operations were negative $0.2 million for the year ended December 31, 2015. Distributable cash flow, EBITDA and adjusted EBITDA are non-GAAP financial measures which are explained in greater detail below under the heading "Use of Non-GAAP Financial Information." The Partnership has also included below a table entitled "Reconciliation of EBITDA, Adjusted EBITDA, and Distributable Cash Flow" in order to show the components of these non-GAAP financial measures and their reconciliation to the most comparable GAAP measurement. Included with this press release are the Partnership's consolidated financial statements as of and for the year ended December 31, 2016 and certain prior periods.  These financial statements should be read in conjunction with the information contained in the Partnership's Annual Report on Form 10-K, to be filed with the SEC on February 17, 2017. An attachment accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/75b5b63e-eaca-4dce-adf1-d056da16cefb. An investors’ conference call to review the fourth quarter results will be held on Thursday, February 16, 2017, at 8:00 a.m. Central Time.  The conference call can be accessed by calling (877) 878-2695.  An audio replay of the conference call will be available by calling (855) 859-2056 from 11:00 a.m. Central Time on February 16, 2017 through 10:59 p.m. Central Time on February 27, 2017.  The access code for the conference call and the audio replay is Conference ID No. 50816933.  The audio replay of the conference call will also be archived on Martin Midstream Partners’ website at www.martinmidstream.com. About Martin Midstream Partners             The Partnership is a publicly traded limited partnership with a diverse set of operations focused primarily in the United States Gulf Coast region. The Partnership's primary business segments include: (1) terminalling, storage and packaging services for petroleum products and by-products; (2) natural gas services, including liquids transportation and distribution services and natural gas storage; (3) sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and (4) marine transportation services for petroleum products and by-products. Statements about the Partnership's outlook and all other statements in this release other than historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements and all references to financial estimates rely on a number of assumptions concerning future events and are subject to a number of uncertainties and other factors, many of which are outside the Partnership's control, which could cause actual results to differ materially from such statements.  While the Partnership believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in anticipating or predicting certain important factors.  A discussion of these factors, including risks and uncertainties, is set forth in the Partnership's annual and quarterly reports filed from time to time with the Securities and Exchange Commission.  The Partnership disclaims any intention or obligation to revise any forward-looking statements, including financial estimates, whether as a result of new information, future events, or otherwise. Use of Non-GAAP Financial Information The Partnership's management uses a variety of financial and operational measurements other than its financial statements prepared in accordance with United States Generally Accepted Accounting Principles (“GAAP”) to analyze its performance. These include: (1) net income before interest expense, income tax expense, and depreciation and amortization (“EBITDA”), (2) adjusted EBITDA and (3) distributable cash flow.  The Partnership's management views these measures as important performance measures of core profitability for its operations and the ability to generate and distribute cash flow, and as key components of its internal financial reporting. The Partnership's management believes investors benefit from having access to the same financial measures that management uses. EBITDA and Adjusted EBITDA.  Certain items excluded from EBITDA and adjusted EBITDA are significant components in understanding and assessing an entity's financial performance, such as cost of capital and historical costs of depreciable assets. The Partnership has included information concerning EBITDA and adjusted EBITDA because it provides investors and management with additional information to better understand the following: financial performance of the Partnership's assets without regard to financing methods, capital structure or historical cost basis; the Partnership's operating performance and return on capital as compared to those of other similarly situated entities; and the viability of acquisitions and capital expenditure projects.  The Partnership's method of computing adjusted EBITDA may not be the same method used to compute similar measures reported by other entities. The economic substance behind the Partnership's use of adjusted EBITDA is to measure the ability of the Partnership's assets to generate cash sufficient to pay interest costs, support its indebtedness and make distributions to its unitholders. Distributable Cash Flow.  Distributable cash flow is a significant performance measure used by the Partnership's management and by external users of its financial statements, such as investors, commercial banks and research analysts, to compare basic cash flows generated by the Partnership to the cash distributions it expects to pay unitholders.  Distributable cash flow is also an important financial measure for the Partnership's unitholders since it serves as an indicator of the Partnership's success in providing a cash return on investment. Specifically, this financial measure indicates to investors whether or not the Partnership is generating cash flow at a level that can sustain or support an increase in its quarterly distribution rates.  Distributable cash flow is also a quantitative standard used throughout the investment community with respect to publicly-traded partnerships because the value of a unit of such an entity is generally determined by the unit's yield, which in turn is based on the amount of cash distributions the entity pays to a unitholder. EBITDA, adjusted EBITDA and distributable cash flow should not be considered alternatives to, or more meaningful than, net income, cash flows from operating activities, or any other measure presented in accordance with GAAP. The Partnership's method of computing these measures may not be the same method used to compute similar measures reported by other entities. Additional information concerning the Partnership is available on the Partnership's website at www.martinmidstream.com or by contacting: These financial statements should be read in conjunction with the financial statements and the accompanying notes and other information included in the Partnership's Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on February 15, 2017. These financial statements should be read in conjunction with the financial statements and the accompanying notes and other information included in the Partnership's Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on February 15, 2017. These financial statements should be read in conjunction with the financial statements and the accompanying notes and other information included in the Partnership's Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on February 15, 2017. These financial statements should be read in conjunction with the financial statements and the accompanying notes and other information included in the Partnership's Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on February 15, 2017. These financial statements should be read in conjunction with the financial statements and the accompanying notes and other information included in the Partnership's Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on February 15, 2017. These financial statements should be read in conjunction with the financial statements and the accompanying notes and other information included in the Partnership's Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on February 15, 2017. The following table reconciles the non-GAAP financial measurements used by management to our most directly comparable GAAP measures for the three and twelve months ended December 31, 2016 and 2015, which represents EBITDA, Adjusted EBITDA and Distributable Cash Flow from continuing operations. The following table reconciles the non-GAAP financial measurements used by management to our most directly comparable GAAP measures for each of the quarters in the year ended December 31, 2015, which represents Distributable Cash Flow from discontinued operations.


PubMed | Resident and MRMC
Type: Journal Article | Journal: Journal of clinical and diagnostic research : JCDR | Year: 2016

An Intra-cranial space occupying lesion (ICSOL)is defined as a mass lesion in the cranial cavity with a diverse aetiology like benign or malignant neoplasm, inflammatory or parasitic lesion, haematoma, or arterio-venous malformation. Central nervous system neoplasms represent a unique, heterogenous population of neoplasms constituting 1.9% of all malignant tumours in India. A broad spectrum of non-neoplastic conditions can mimic a brain tumour, both clinically and radiologically and these patients undergo biopsy. In such cases, the pathologist can readily differentiate between neoplastic and non-neoplastic imitators.The present study attempts to provide preliminary data on morphological patterns of intracranial lesions in North Karnataka region and to study clinicopathological spectrum with correlation of radiological findings of ICSOL. Special emphasis is made on the utility of special stains and IHC markers in CNS tumours.This retrospective and prospective descriptive study was performed on biopsy specimen of ICSOL received from Departmnet of Neurosurgery, Basaveshwar Teaching Hospital, Kalaburgi. The study period was from January 2012 to June 2013 retrospectively and July 2013 to June 2015 prospectively. All specimens were preserved in 10% formalin and allowed to fix for 24 hours. The haematoxylin and eosin stained sections of the CNS lesions were obtained by routine processing and paraffin embedding. Special stains and IHC were done wherever appropriate.Sixty two cases of CNS lesions were studied, of which 12 (19.4%) cases were non neoplastic with six (50%) being cystic lesions and four (33.4%) were cerebral abscess. The neoplastic lesions comprised of 50 (80.6%) cases, which included 48 (96%) primary and two (4%) metastatic lesions. Among primary tumours, gliomas constituted the largest category of 24 (50%) cases with 16.7% being Glioblastoma Multiforme (GBM) and pilocytic astrocytomas each, followed by schwannomas (14%) and meningothelial tumours (12%). Majority were Grade I among gliomas and tumour of meninges with 37.5% and 87.5% respectively. Mean age of the patients was 26.7211.2 (range: 0.4 to 80) years. Male to female ratio was 1:1.14. GFAP was demonstrated in astrocytomas, mixed gliomas and gliosarcoma.The surgical pathologist plays an important role in accurate diagnosis of various lesions of CNS which will be of immense help for patient prognosis and treatment. Immunohistochemistry is currently being employed to assist in the diagnosis of brain tumours.


Gurulingappa,MRMC | Aleem M.A.,MNR Medical College | Awati M.N.,MRMC | Adarsh S.,MRMC
Journal of Clinical and Diagnostic Research | Year: 2012

Background and objectives: Laryngoscopy and tracheal intubation is invariably associated with a reflex sympathetic pressor response resulting in elevated heart rate and blood pressures. This may prove detrimental in high risk patients. Objective of this study is to compare the effects of lignocaine and fentanyl in attenuation of this pressor response to laryngoscopy and tracheal intubation. Methods: Seventy five ASA I and II status normotensive patients scheduled for elective surgical procedures were selected randomly and divided into three groups of 25 each. All patients received premedication with pentazocine 0.05mg/kg i.v., atropine 0.01mg/ kg intramuscularly and midazolam 0.01mg/kg i.v. half an hour prior to induction. Induction of anesthesia was standardized for all patients who received, thiopentone 5 mg/kg i.v. and and were relaxed with succinylcholine 2mg/kg i.v. The first group received fentanyl 4micrograms/kg i.v bolus, the second group received lignocaine 1.5mg i.v bolus and then third group received placebo (normal saline), 5 minutes before laryngoscopy and intubation. HR, systolic, diastolic blood pressure were recorded noninvasively one day priorly B, Before induction 0 postinduction, 1,2,3,4 and 5 minutes from the onset of laryngoscopy. Results: After intubation incidence of tachycardia (HR>100/min) was significantly greater in placebo and lignocaine group than in fentanyl group (p<0.05). Rise in SBP and DBP were also statistically significant in placebo and lignocaine group than in fentanyl group (p<0.05). Conclusion: Attenuation of pressor response is seen both with lignocaine and fentanyl. Of the two drugs fentanyl 4mgicrogram i.v. bolus provides a consistent, reliable and effective attenuation as compared to lignocaine 1.5mg/kg iv. bolus.


News Article | November 1, 2016
Site: www.prweb.com

Mark Roberts Motion Control, industry leaders in motion control robotics have partnered up with Rite Media group, a full service production studio headquartered in Atlanta, Georgia. ‘The group of talented filmmakers are truly making waves in the rapidly growing Atlanta, Georgia entertainment market. With their love for technology and relentless pursuit in pushing the envelope, we couldn’t have asked for a better partner in our quest to popularize motion control robotics around the world. We at MRMC are truly excited to see what comes from this group of innovators.’ “For RiTE, The Bolt High Speed Cinebot was of particular interest as it is the only robot of its kind that can move at such speeds with exact precision and programmable, repeatable moves. MRMC's unrivaled technical ingenuity is embodied within the capabilities of Bolt which made it a natural fit for RiTE.” MRMC manufacture, rent and sell motion control equipment for special and visual effects. Their robotics are used all over the world, often in major blockbuster movies – Avengers, Skyfall, X-Men and Harry Potter to name a few. MRMC’s track record in technical and engineering excellence has earned the company critical acclaim — including an Oscar for technical achievement. RiTE Media Group will be a local source in Atlanta for renting the Bolt. Check out RiTE Media Group’s accomplishments in their Megareel here: http://Vimeo.com/ritemediagroup/megareel


Hema Neelakantaiah A.,MRMC | Ravindra R.S.,MRMC | Karnappa A.S.,MRMC
Journal of Clinical and Diagnostic Research | Year: 2016

Introduction: An “Intra-cranial space occupying lesion” (ICSOL) is defined as a mass lesion in the cranial cavity with a diverse aetiology like benign or malignant neoplasm, inflammatory or parasitic lesion, haematoma, or arterio-venous malformation. Central nervous system neoplasms represent a unique, heterogenous population of neoplasms constituting 1. 9% of all malignant tumours in India. A broad spectrum of non-neoplastic conditions can mimic a brain tumour, both clinically and radiologically and these patients undergo biopsy. In such cases, the pathologist can readily differentiate between neoplastic and non-neoplastic imitators. Aim: The present study attempts to provide preliminary data on morphological patterns of intracranial lesions in North Karnataka region and to study clinicopathological spectrum with correlation of radiological findings of ICSOL. Special emphasis is made on the utility of special stains and IHC markers in CNS tumours. Materials and Methods: This retrospective and prospective descriptive study was performed on biopsy specimen of ICSOL received from Departmnet of Neurosurgery, Basaveshwar Teaching Hospital, Kalaburgi. The study period was from January 2012 to June 2013 retrospectively and July 2013 to June 2015 prospectively. All specimens were preserved in 10% formalin and allowed to fix for 24 hours. The haematoxylin and eosin stained sections of the CNS lesions were obtained by routine processing and paraffin embedding. Special stains and IHC were done wherever appropriate. R esults: Sixty two cases of CNS lesions were studied, of which 12 (19. 4%) cases were non neoplastic with six (50%) being cystic lesions and four (33. 4%) were cerebral abscess. The neoplastic lesions comprised of 50 (80. 6%) cases, which included 48 (96%) primary and two (4%) metastatic lesions. Among primary tumours, gliomas constituted the largest category of 24 (50%) cases with 16. 7% being Glioblastoma Multiforme (GBM) and pilocytic astrocytomas each, followed by schwannomas (14%) and meningothelial tumours (12%). Majority were Grade I among gliomas and tumour of meninges with 37. 5% and 87. 5% respectively. Mean age of the patients was 26. 72±11. 2 (range: 0. 4 to 80) years. Male to female ratio was 1: 1. 14. GFAP was demonstrated in astrocytomas, mixed gliomas and gliosarcoma. C onclusion: The surgical pathologist plays an important role in accurate diagnosis of various lesions of CNS which will be of immense help for patient prognosis and treatment. Immunohistochemistry is currently being employed to assist in the diagnosis of brain tumours. © 2016, Journal of Clinical and Diagnostic Research. All rights reserved.


Mudda V.,MRMC | Manjunatha K.,MRMC
Indian Journal of Forensic Medicine and Toxicology | Year: 2013

For Blunt Injuries of Abdomen majority of the cases i.e. 78.18% were of accidental, 18.18%were homicidal and 3.6% suicidal in nature. Immediate cause of death was shock and hemorrhage. Visceral injuries of the abdomen following blunt trauma present a great medico-legal problem to the forensic experts. We had a case of road traffic accident with fatal blunt abdominal trauma which had no external injuries. Rupture of superior mesenteric vessels, injuries to left psoas muscle, spleen, both kidneys and fracture of left hemi pelvis present internally. We also observed 1500ml of blood in the peritoneal cavity. Death is imminent in such fatal cases. Availability of first aid, transportation, tertiary trauma care facilities, availability of diagnostic procedures, intensity with which medical care is offered contribute to the survival of the accident victim. The main significance of blunt trauma abdomen is delay and difficulty in diagnosis, especially when there is minimal signs and symptoms to warrant an exploratory laparotomy. Early detection and emergency surgical intervention when necessary are critical in improving the outcome of treatment.

Loading MRMC collaborators
Loading MRMC collaborators